PhD fellowship in monogenetic diabetes
Denne stilling er desværre ikke længere ledig.
Se alle ledige stillinger
Gentofte
A PhD fellowship is available at Steno Diabetes Center Copenhagen (SDCC), Gentofte Hospital, University of Copenhagen, Denmark. The position is open for medical doctors with interest in clinical research within the cross field of monogenetic diabetes and modern treatment by September 1st, 2021.
The project is a close collaboration between several research environments within the Capital Region of Denmark, namely SDCC, Center for Clinical Metabolic Research CCMR) and the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark. The clinical studies will be carried out at SDCC/CCMR where researcher and technical staff have a pronounced expertise and devotion to clinical metabolic research. The combination of a high-quality research environment together with a friendly and sociable atmosphere is characteristic for both SDCC and CCMR.
The project -will include patients with mutations in hepatocyte nuclear factor-1 alpha (HNF1A) which accounts for 0.5% of all cases of diabetes. The risk of diabetic complications in patients with HNF1A-MODY are comparable to that of patients with type 2 diabetes, and glycaemic control and management of risk factors are crucial for a good prognosis. First-line treatment of HNF1A-MODY is sulfonylurea (SU); however, there is limited evidence on second-line and third-line treatment options. Furthermore, studies have demonstrated that glycaemic control of a large proportion of patients with HNF1A-MODY are not at target and that ~35% of patients are treated with insulin although SU has been shown to be superior in terms of glycaemic control. Thus, there is a great potential for optimising glycaemic control by applying modern glucose-lowering agents which may reduce the risk of both microvascular and macrovascular complications in patients with HNF1A-MODY. Sodium glucose linked transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) are known for their cardiovascular and renal protective effects in type 2 diabetes. In patients with HNF1A-MODY, SGLT2i long-term efficacy and safety is currently unknown. In this PhD-proposal, we aim at delineating the potential of SGLT2i in HNF1A-MODY and we will plan a multiple therapy study with treatment based on SU, incretin-based therapy and SGLT2i in patients with HNF1A-MODY in a large interventional setting.
The job - the PhD-project contains three individual clinical studies. The PhD student will work closely together with the researchers in the research group and be responsible for writing protocols, recruiting participants, collecting and analysing data and finally writing manuscripts aimed for publication in scientific journals.
Terms - the PhD candidate should be a medical doctor (MD) and will be offered a full-time position for a period of three years. Employment will be in accordance with the relevant collective agreement within the Capital Region of Denmark.
Contact - for further information please contact: Professor Tina Vilsbøll, MD DMSc (Mobile: +45 4094 0825).
About Steno Diabetes Center Copenhagen - Steno Diabetes Center Copenhagen (SDCC) is a visionary diabetes center for the entire Capital Region specialized in the treatment, research and prevention of diabetes and in the education of healthcare professionals in diabetes. SDCC is the largest diabetes clinic in Scandinavia and treats more than 9,000 people with diabetes from the Capital Region each year. Read more on www.sdcc.dk and follow SDCC on Twitter and LinkedIn.
Kilde: Jobnet.dk
The project is a close collaboration between several research environments within the Capital Region of Denmark, namely SDCC, Center for Clinical Metabolic Research CCMR) and the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Denmark. The clinical studies will be carried out at SDCC/CCMR where researcher and technical staff have a pronounced expertise and devotion to clinical metabolic research. The combination of a high-quality research environment together with a friendly and sociable atmosphere is characteristic for both SDCC and CCMR.
The project -will include patients with mutations in hepatocyte nuclear factor-1 alpha (HNF1A) which accounts for 0.5% of all cases of diabetes. The risk of diabetic complications in patients with HNF1A-MODY are comparable to that of patients with type 2 diabetes, and glycaemic control and management of risk factors are crucial for a good prognosis. First-line treatment of HNF1A-MODY is sulfonylurea (SU); however, there is limited evidence on second-line and third-line treatment options. Furthermore, studies have demonstrated that glycaemic control of a large proportion of patients with HNF1A-MODY are not at target and that ~35% of patients are treated with insulin although SU has been shown to be superior in terms of glycaemic control. Thus, there is a great potential for optimising glycaemic control by applying modern glucose-lowering agents which may reduce the risk of both microvascular and macrovascular complications in patients with HNF1A-MODY. Sodium glucose linked transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) are known for their cardiovascular and renal protective effects in type 2 diabetes. In patients with HNF1A-MODY, SGLT2i long-term efficacy and safety is currently unknown. In this PhD-proposal, we aim at delineating the potential of SGLT2i in HNF1A-MODY and we will plan a multiple therapy study with treatment based on SU, incretin-based therapy and SGLT2i in patients with HNF1A-MODY in a large interventional setting.
The job - the PhD-project contains three individual clinical studies. The PhD student will work closely together with the researchers in the research group and be responsible for writing protocols, recruiting participants, collecting and analysing data and finally writing manuscripts aimed for publication in scientific journals.
Terms - the PhD candidate should be a medical doctor (MD) and will be offered a full-time position for a period of three years. Employment will be in accordance with the relevant collective agreement within the Capital Region of Denmark.
Contact - for further information please contact: Professor Tina Vilsbøll, MD DMSc (Mobile: +45 4094 0825).
About Steno Diabetes Center Copenhagen - Steno Diabetes Center Copenhagen (SDCC) is a visionary diabetes center for the entire Capital Region specialized in the treatment, research and prevention of diabetes and in the education of healthcare professionals in diabetes. SDCC is the largest diabetes clinic in Scandinavia and treats more than 9,000 people with diabetes from the Capital Region each year. Read more on www.sdcc.dk and follow SDCC on Twitter and LinkedIn.
Kilde: Jobnet.dk
Information og data
Denne ledige stilling har jobtypen "Forsker", og befinder sig i kategorien "Sundhed og forskning".
Arbejdsstedet er beliggende i Gentofte.
Jobbet er oprettet på vores service den 1.7.2021, men kan have været deaktiveret og genaktiveret igen.
Dagligt opdateret: Dette job opdateres dagligt ud fra jobudbyderens hjemmeside via vores søgemaskineteknologi og er aktivt lige nu.
- Forsker
- Gentofte
- Tirsdag den 20. juli 2021
Lignende jobs
-
Lead/Specialist Research Scientist within Bioassay...
Would you like to make an impact on improving the quality of life of millions suffering from allergic diseases? Do you have an analytical and curious mindset? Do like to be part of a drug discovery..Få mere info- Forsker
- Hørsholm
-
Innovate and Inspire as a Biotech Research Scienti...
Do you thrive exploring innovative new ways to solve scientific challenges? At [xxxxx]TechBio LAB, we’re a team of thinkers, doers, and collaborators who believe in the power of innovation to .Få mere info- Forsker
- Hørsholm
-
PhD scholarship in Reproductive Toxicology - DTU F...
Få mere info- Forsker
- Klampenborg
-
PhD scholarship in Human Decision-Making and Immer...
Få mere info- Forsker
- Klampenborg
Statistik over udbudte jobs som forskere i Gentofte
Herunder ser du udviklingen i udbudte forsker i Gentofte over tid. Bemærk at jobs der ikke har en bestemt geografi ikke er medtaget i tabellen. I den første kolonne ser du datoen. I den næste kolonne ser du det samlede antal forskere.
Se flere statistikker her:
Statistik over udbudte forskere i Gentofte over tid
| Dato | Alle jobs som forskere |
|---|---|
| 23. december 2024 | 2 |
| 22. december 2024 | 2 |
| 21. december 2024 | 3 |
| 20. december 2024 | 2 |
| 19. december 2024 | 2 |
| 18. december 2024 | 2 |
| 17. december 2024 | 2 |
| 16. december 2024 | 1 |
| 15. december 2024 | 1 |
| 14. december 2024 | 2 |
| 12. december 2024 | 1 |
| 11. december 2024 | 1 |
| 10. december 2024 | 1 |
| 9. december 2024 | 1 |
| 8. december 2024 | 1 |
| 7. december 2024 | 1 |
| 6. december 2024 | 1 |